Depression in pediatric patients with type 1 diabetes

Jennifer A. Tilleman, Edward M. DeSimone, Elizabeth Scheffel

Research output: Contribution to specialist publicationArticle

Abstract

Depression in pediatric patients with type 1 diabetes (T1D) is a growing area of discussion. A diagnosis of T1D requires pediatric patients and their families to make drastic lifestyle changes. Improper coping skills can negatively affect the patient’s life and jeopardize overall health, as signaled by poor glycemic control and A1C readings. The mainstay of treatment for depression in pediatric patients with T1D is psychotherapy. Medication is warranted in certain cases, and currently only two agents have FDA indications for pediatric depression: fluoxetine and escitalopram. The use of antidepressants in pediatric patients with T1D requires thorough counseling by a pharmacist to ensure optimal outcomes.

Original languageEnglish
Pages27-30
Number of pages4
Volume41
No5
Specialist publicationU.S. Pharmacist
StatePublished - May 1 2016

Fingerprint

Pediatrics
Medical problems
Type 1 Diabetes Mellitus
Depression
Citalopram
Fluoxetine
Psychological Adaptation
Pharmacists
Psychotherapy
Antidepressive Agents
Life Style
Counseling
Reading
Health

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this

Tilleman, J. A., DeSimone, E. M., & Scheffel, E. (2016). Depression in pediatric patients with type 1 diabetes. U.S. Pharmacist, 41(5), 27-30.

Depression in pediatric patients with type 1 diabetes. / Tilleman, Jennifer A.; DeSimone, Edward M.; Scheffel, Elizabeth.

In: U.S. Pharmacist, Vol. 41, No. 5, 01.05.2016, p. 27-30.

Research output: Contribution to specialist publicationArticle

Tilleman, JA, DeSimone, EM & Scheffel, E 2016, 'Depression in pediatric patients with type 1 diabetes' U.S. Pharmacist, vol. 41, no. 5, pp. 27-30.
Tilleman, Jennifer A. ; DeSimone, Edward M. ; Scheffel, Elizabeth. / Depression in pediatric patients with type 1 diabetes. In: U.S. Pharmacist. 2016 ; Vol. 41, No. 5. pp. 27-30.
@misc{dee06a72b4ea467f9a15316a7b07d59b,
title = "Depression in pediatric patients with type 1 diabetes",
abstract = "Depression in pediatric patients with type 1 diabetes (T1D) is a growing area of discussion. A diagnosis of T1D requires pediatric patients and their families to make drastic lifestyle changes. Improper coping skills can negatively affect the patient’s life and jeopardize overall health, as signaled by poor glycemic control and A1C readings. The mainstay of treatment for depression in pediatric patients with T1D is psychotherapy. Medication is warranted in certain cases, and currently only two agents have FDA indications for pediatric depression: fluoxetine and escitalopram. The use of antidepressants in pediatric patients with T1D requires thorough counseling by a pharmacist to ensure optimal outcomes.",
author = "Tilleman, {Jennifer A.} and DeSimone, {Edward M.} and Elizabeth Scheffel",
year = "2016",
month = "5",
day = "1",
language = "English",
volume = "41",
pages = "27--30",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Depression in pediatric patients with type 1 diabetes

AU - Tilleman, Jennifer A.

AU - DeSimone, Edward M.

AU - Scheffel, Elizabeth

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Depression in pediatric patients with type 1 diabetes (T1D) is a growing area of discussion. A diagnosis of T1D requires pediatric patients and their families to make drastic lifestyle changes. Improper coping skills can negatively affect the patient’s life and jeopardize overall health, as signaled by poor glycemic control and A1C readings. The mainstay of treatment for depression in pediatric patients with T1D is psychotherapy. Medication is warranted in certain cases, and currently only two agents have FDA indications for pediatric depression: fluoxetine and escitalopram. The use of antidepressants in pediatric patients with T1D requires thorough counseling by a pharmacist to ensure optimal outcomes.

AB - Depression in pediatric patients with type 1 diabetes (T1D) is a growing area of discussion. A diagnosis of T1D requires pediatric patients and their families to make drastic lifestyle changes. Improper coping skills can negatively affect the patient’s life and jeopardize overall health, as signaled by poor glycemic control and A1C readings. The mainstay of treatment for depression in pediatric patients with T1D is psychotherapy. Medication is warranted in certain cases, and currently only two agents have FDA indications for pediatric depression: fluoxetine and escitalopram. The use of antidepressants in pediatric patients with T1D requires thorough counseling by a pharmacist to ensure optimal outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84969815990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969815990&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84969815990

VL - 41

SP - 27

EP - 30

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -